Loading...
•
Mar 31
Aclaris Therapeutics Q1 2025 Earnings Report
Aclaris Therapeutics reported its first quarter 2025 financial results, highlighting progress in its clinical programs and an extended cash runway.
Key Takeaways
Aclaris Therapeutics reported a net loss of $15.1 million for the first quarter of 2025, an improvement from the $16.9 million loss in Q1 2024. Total revenue for the quarter was $1.5 million. The company ended the quarter with $190.5 million in cash, cash equivalents, and marketable securities, extending its cash runway through the first half of 2028.
Net loss improved to $15.1 million in Q1 2025 from $16.9 million in Q1 2024.
Total revenue for Q1 2025 was $1.5 million, down from $2.4 million in Q1 2024.
Cash, cash equivalents, and marketable securities stood at $190.5 million as of March 31, 2025, extending the cash runway through the first half of 2028.
The company plans to initiate a Phase 2 trial for bosakitug in Atopic Dermatitis and a Phase 1 trial for ATI-052 in Q2 2025.
Aclaris Therapeutics
Aclaris Therapeutics
Aclaris Therapeutics Revenue by Segment
Revenue by Segment
Contract research Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
Aclaris Therapeutics expects its current cash, cash equivalents, and marketable securities to fund operations through the first half of 2028, supporting its preclinical and clinical development plans. The company aims to prioritize clinical execution and achieve development milestones.
Positive Outlook
- Expected cash runway extends through the first half of 2028, fully funding preclinical and clinical development plans.
- Initiation of enrollment in a placebo-controlled two-arm Phase 2 trial for bosakitug in Atopic Dermatitis expected in Q2 2025.
- IND application for bispecific antibody ATI-052 cleared by U.S. FDA, with Phase 1 trial initiation expected in Q2 2025.
- Top-line results from Phase 2a trial for ATI-2138 in Atopic Dermatitis expected in June 2025.
- Injunction against Sun Pharmaceuticals lifted, potentially providing an additional opportunity for non-dilutive financing.
Challenges Ahead
- Further global development of bosakitug in respiratory indications will be dependent on partnerships.
- The company's ability to enter into strategic partnerships on commercially reasonable terms is uncertain.
- Reliance on third parties for clinical trials over which the company may not always have full control.
- Uncertainty regarding the macroeconomic environment could impact operations.
- Risks and uncertainties described in the 'Risk Factors' section of Aclaris' Annual Report on Form 10-K for the year ended December 31, 2024, could cause actual results to differ materially.